Scott Sponheim

Dr. Scott Sponheim


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2014 in Brain Imaging and Behavior
Verified
Journal Article
Open access
PDF file
PTPaul M. Thompson
Paul M. Thompson
JSJason L. Stein
Jason L. Stein
SMSarah E. Medland
Sarah E. Medland
DHDerrek P. Hibar
Derrek P. Hibar
AVAlejandro Arias Vasquez
Alejandro Arias Vasquez
WDWayne Drevets
Wayne Drevets
The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium is a collaborative network of researchers working together on a range of large-scale studies that integrate data from 70 institutions worldwide. Organized into Working Groups that tackle questions in neuroscience, genetics, and medicine, ENIGMA studies have analyzed neuroimaging data from over 12,826 subjects. In addition, data from 12,171 individuals were provided by the CHARGE consortium for replication of findings, in a total of 24,997 subjects. By meta-analyzing results from many sites, ENIGMA has detected factors that affect the brain that no individual site could detect on its own, and that require larger numbers of subjects than any individual neuroimaging study has currently collected. ENIGMA’s first project was a genome-wide association study identifying common variants in the genome associated with hippocampal volume or intracranial volume. Continuing work is exploring genetic associations with subcortical volumes (ENIGMA2) and white matter microstructure (ENIGMA-DTI). Working groups also focus on understanding how schizophrenia, bipolar illness, major depression and attention deficit/hyperactivity disorder (ADHD) affect the brain. We review the current progress of the ENIGMA Consortium, along with challenges and unexpected discoveries made on the way.

8 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CNCaroline Nievergelt
Caroline Nievergelt
AMAdam X. Maihofer
Adam X. Maihofer
TKTorsten Klengel
Torsten Klengel
EAElizabeth G. Atkinson
Elizabeth G. Atkinson
CCChia-Yen Chen
Chia-Yen Chen
KKKarestan C. Koenen
Karestan C. Koenen
The risk of posttraumatic stress disorder (PTSD) following trauma is heritable, but robust common variants have yet to be identified. In a multi-ethnic cohort including over 30,000 PTSD cases and 170,000 controls we conduct a genome-wide association study of PTSD. We demonstrate SNP-based heritability estimates of 5–20%, varying by sex. Three genome-wide significant loci are identified, 2 in European and 1 in African-ancestry analyses. Analyses stratified by sex implicate 3 additional loci in men. Along with other novel genes and non-coding RNAs, a Parkinson’s disease gene involved in dopamine regulation, PARK2, is associated with PTSD. Finally, we demonstrate that polygenic risk for PTSD is significantly predictive of re-experiencing symptoms in the Million Veteran Program dataset, although specific loci did not replicate. These results demonstrate the role of genetic variation in the biology of risk for PTSD and highlight the necessity of conducting sex-stratified analyses and expanding GWAS beyond European ancestry populations.

18 April 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CNCaroline Nievergelt
Caroline Nievergelt
AMAdam X. Maihofer
Adam X. Maihofer
EAElizabeth G. Atkinson
Elizabeth G. Atkinson
CCChia-Yen Chen
Chia-Yen Chen
KCKarmel W. Choi
Karmel W. Choi
KKKarestan C. Koenen
Karestan C. Koenen

12 June 2013 in Neuroinformatics
Verified
Journal Article
Closed access
PDF file
RGRandy L. Gollub
Randy L. Gollub
JSJody M. Shoemaker
Jody M. Shoemaker
MKMargaret D. King
Margaret D. King
TWTonya White
Tonya White
SEStefan Ehrlich
Stefan Ehrlich
NANancy C. Andreasen
Nancy C. Andreasen

31 October 2016 in American Journal of Psychiatry
Verified
Journal Article
Closed access
AKAntonia N. Kaczkurkin
Antonia N. Kaczkurkin
PBPhilip C. Burton
Philip C. Burton
SCShai M. Chazin
Shai M. Chazin
AMAdrienne B. Manbeck
Adrienne B. Manbeck
TETori Espensen-Sturges
Tori Espensen-Sturges
SLShmuel Lissek
Shmuel Lissek

28 December 2014 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
CGCota Navin Gupta
Cota Navin Gupta
VCVince D. Calhoun
Vince D. Calhoun
SRSrinivas Rachakonda
Srinivas Rachakonda
JCJiayu Chen
Jiayu Chen
VPVeena Patel
Veena Patel
Jessica TurnerJessica Turner
Jessica Turner
Analyses of gray matter concentration (GMC) deficits in patients with schizophrenia (Sz) have identified robust changes throughout the cortex. We assessed the relationships between diagnosis, overall symptom severity, and patterns of gray matter in the largest aggregated structural imaging dataset to date. We performed both source-based morphometry (SBM) and voxel-based morphometry (VBM) analyses on GMC images from 784 Sz and 936 controls (Ct) across 23 scanning sites in Europe and the United States. After correcting for age, gender, site, and diagnosis by site interactions, SBM analyses showed 9 patterns of diagnostic differences. They comprised separate cortical, subcortical, and cerebellar regions. Seven patterns showed greater GMC in Ct than Sz, while 2 (brainstem and cerebellum) showed greater GMC for Sz. The greatest GMC deficit was in a single pattern comprising regions in the superior temporal gyrus, inferior frontal gyrus, and medial frontal cortex, which replicated over analyses of data subsets. VBM analyses identified overall cortical GMC loss and one small cluster of increased GMC in Sz, which overlapped with the SBM brainstem component. We found no significant association between the component loadings and symptom severity in either analysis. This mega-analysis confirms that the commonly found GMC loss in Sz in the anterior temporal lobe, insula, and medial frontal lobe form a single, consistent spatial pattern even in such a diverse dataset. The separation of GMC loss into robust, repeatable spatial patterns across multiple datasets paves the way for the application of these methods to identify subtle genetic and clinical cohort effects.